secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-010342
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues CRL for Atara's EBVALLO BLA, reversing prior stance on trial adequacy
--------------------------------------------------------------------------------

- FDA CRL received Jan 9, 2026; confirms GMP issues resolved but claims ALLELE trial inadequate for accelerated approval.
- Atara and partner Pierre Fabre plan to request Type A meeting within 45 days to seek path forward.
- Cash, cash equivalents and short-term investments as of Dec 31, 2025: approximately $8.5M.
- Atara implemented ~90% headcount reduction and reduced ARC lease liability by ~65% in 2025.
- Amendment to PFM agreement: approval milestone reduced to $31M, with potential $15M commercial milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/0001193125-26-010342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-010342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer